{"metadata": {"organization_names": [], "person_names_verified": [], "organization_names_verified": ["redhill\u2019s development", "redhill biopharma ltd."], "vars": {"Party": {"IntelGenx Technologies Corp.": "[[Party 1]]"}}, "entities_rejected": [], "person_names": [], "agreement_id": "2148b0a3916623396081b846adbe7380784fab16e5f0375fa4c1cb3627074869", "topics": [], "terms": ["*   Primary responsibility for the development of the Product and the final vote on development, regulatory and manufacturing decisions *", "*   Primary responsibility for the licensing and partnering of the Product and the final vote on partnering/licensing/commercialization decisions. *", "*   Within 30 days of Closing: [****", "*   Within 30 days of filing and acceptance of the NDA by the US FDA (\u201c**", "*   Within 30 days of successful completion of scale up, process development, and production of pivotal batches (\u201c**", "*   Within 30 days of the Product marketing approval (approval of the NDA of the Product) by the US FDA (\u201c**", "*   Within 60 days of Closing: [****", "*   Within 7 days of Closing: [**", "****", "****] **", "****] of Proceeds, RedHill shall receive [****", "****] of any and all Proceeds exceeding [****", "****] \u0096 [****", "**ANNEX A**", "**Annex B**", "**CONFIDENTIAL TREATMENT REQUESTED**", "**Collaboration Project**", "**Confidentiality**", "**Decision-making**", "**Diligence Obligation**", "**Diligence**", "**Exclusivity and Due**", "**Field**", "**Governing Law**", "**IP Ownership**", "**In territories where RedHill sells the Product on its own:**", "**In territories where the Product is marketed by a third party marketing**", "**Limited Term**", "**Payments**", "**Proceeds**", "**Product**", "**R&D, Manufacturing**", "**Redacted portions are indicated by [****", "**Redacted portions filed separately with the SEC pursuant**", "**Responsibilities and**", "**Resulting**", "**Rights in the Product**", "**Steering Committee**", "**Term Sheet: [****", "**Territory**", "**] and IGXT will receive [****", "**and other Data**", "**and**", "**partner**", "**to the confidential treatment request**", "**\u201cDiligence Obligation\u201d)**", "*actually received*", "\u201c**Agreement**\u201d", "\u201c**Breakup Fee**\u201d", "\u201c**Closing**\u201d", "\u201c**Development Milestone I\u201d**): [****]*   Within 30 days of filing and acceptance of the NDA by the US FDA (\u201c**Development Milestone II\u201d**): [****]*   Within 30 days of the Product marketing approval (approval of the NDA of the Product) by the US FDA (\u201c**Development Milestone III\u201d", "\u201c**Due Diligence Exclusivity Period**\u201d", "\u201c**IGXT**\u201d", "\u201c**Parties**\u201d", "\u201c**Proceeds**\u201d", "\u201c**Project**\u201d", "\u201c**RedHill**\u201d", "\u201c**SC**\u201d", "\u201c**Term Sheet**\u201d", "\u201d**). For the avoidance of any doubt, the Initial Proceeds Split will only apply once for the Product, and not per territory or per third party partner. Therefore, following the Initial Proceeds Split, RedHill will receive [****", "\u201d**): [****"]}}